Research programme: neurodegenerative disease therapeutics - BioCrea
Latest Information Update: 16 Jul 2016
At a glance
- Originator biocrea GmbH
- Developer biocrea GmbH; Technische Universitat Dresden
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Germany
- 22 Apr 2013 Early research in Amyotrophic lateral sclerosis in Germany (unspecified route)